3KaneJK, Carson WH, saha AR, et al. Efficacy and safety of airpiprazol and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin psychiatry, 2002, sep, 63 (9): 763
4McGavinJK, Goak L. Aripiprazole. CNC Drugs, 2002,16(11): 779
5Yoloi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic tomography and raclopride. Neuropsychopharmacolog, 2002,27(2): 248
6Inoue A, seto M, Sugita S, et al.differential effects on dopamine receptor and prolactin gene expression by haloperdol and aripiprazole in the rat ptiuitary. Brain Res Mol Brain Res, 1998,55:285
7Stahl SM. dopamine system stabilizers, ariplprazole, and the next generation of antipsyehoties, partl, "Goldilocks" actions at dopamine receptors. J clin psychiatry, 2001,62 (11): 841
3[2]Disayavanish C, Srisurapanont M, Udomratn P, et al. Guideline for the pharmacotherapy of treatment-resistant schizophrenia. J Med Assoc Thai, 2000 Jun, 83(6) : 579 ～589
4[3]Robert R. Conley, Robert W. Buchanan. Evaluation of treatment-resistant schizohrenia. Schizophrenia Bulletin, 1997, 23 (4) : 663 ～669
5[8]Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized doubleblind study. The Risperidone Study Group. Am J Psychiatry, 1998Apr, 155(4) : 499 ～504
6[9]Flynn SW, MacEwan GW, Altman S, et al. An open comparison of clozapine and risperdone in treatment-resistant schizophrenia. Pharmacopsychiatry, 1998 Jan, 31 ( 1 ) : 25 ～ 29
7[10]Wahlbeck K, Cheine M, Tuisku K, et al. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.Prog Neuropsychopharmacol Biol Psychiatry, 2000 Aug, 24 ( 6 ) :911 ～922
8[1]Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 ( 1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995 Jul, 274( 1 ) :329 ～ 336
9[2]Fleishhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003, 105 ～ 117
10[3]Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[ 4-( 4-phenyl-1-piperazinyl ) butoxy ]-3, 4-dthydro-2 (1H)-quinolinone derivatives. J Med Chem, 1998 Feb, 41 : 658 ～667
